Home » Stocks » ANAB

AnaptysBio, Inc. (ANAB)

Stock Price: $21.72 USD -0.35 (-1.59%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 594.40M
Revenue (ttm) 75.00M
Net Income (ttm) -19.93M
Shares Out 27.30M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $21.72
Previous Close $22.07
Change ($) -0.35
Change (%) -1.59%
Day's Open 21.94
Day's Range 20.80 - 21.91
Day's Volume 258,116
52-Week Range 13.92 - 35.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...

6 days ago - GlobeNewsWire

AnaptysBio Inc's (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio...

1 month ago - Benzinga

This analyst is excited about the company's prospects.

1 month ago - The Motley Fool

A phoenix may well rise from the ashes of a disappointing clinical trial.

1 month ago - The Motley Fool

AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.

1 month ago - Zacks Investment Research

The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.

1 month ago - The Motley Fool

AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of imsidolimab for palmoplantar pustulosis (PPP). The study failed to meet its primary endpoint of impro...

1 month ago - Benzinga

There was some encouraging news from across the Atlantic.

1 month ago - The Motley Fool

Perhaps no news is bad news for the ambitious biotech.

1 month ago - The Motley Fool

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.

2 months ago - The Motley Fool

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...

Other stocks mentioned: EPIX, PACB
2 months ago - Benzinga

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...

3 months ago - GlobeNewsWire

AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology. A...

4 months ago - Seeking Alpha

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...

5 months ago - GlobeNewsWire

AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.

6 months ago - Zacks Investment Research

SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...

6 months ago - GlobeNewsWire

SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical nee...

7 months ago - GlobeNewsWire

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.

7 months ago - Business Wire

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co...

8 months ago - GlobeNewsWire

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical need...

8 months ago - GlobeNewsWire

Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement

8 months ago - GlobeNewsWire

Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer

9 months ago - GlobeNewsWire

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co...

9 months ago - GlobeNewsWire

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

9 months ago - Zacks Investment Research

Is (ANAB) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

The beaten-up biopharma provided an update that revved up interest in its pipeline.

10 months ago - The Motley Fool

NEW YORK, May 19, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ:ANAB) of the May 26, 2020 ...

10 months ago - PRNewsWire

NEW YORK, May 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7,...

11 months ago - PRNewsWire

As of late, it has definitely been a great time to be an investor AnaptysBio

11 months ago - Zacks Investment Research

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Key clinical trial results this quarter will determine the better buy.

Other stocks mentioned: EXEL
11 months ago - The Motley Fool

This antibody drug developer can be had for fire-sale prices.

1 year ago - The Motley Fool

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.

Other stocks mentioned: BLUE, EXEL
1 year ago - The Motley Fool

Worries about a coronavirus impact don't make sense.

Other stocks mentioned: BLUE, EDIT
1 year ago - The Motley Fool

A pair of black swans crushed these three healthcare stocks today.

Other stocks mentioned: CODX, NVAX
1 year ago - The Motley Fool

After a rough 2019, investors are excited about the biotech's prospects in the year ahead.

1 year ago - The Motley Fool

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Falling knives are companies whose share prices have declined more than 59% over the past 12 months.

Other stocks mentioned: TC
1 year ago - GuruFocus

AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its Net Cash Per Share

1 year ago - Seeking Alpha

AnaptysBio has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

AnaptysBio (ANAB) earnings for the antibody development company's third quarter of 2019 have ANAB stock taking a dive on Friday.

1 year ago - InvestorPlace

A clinical trial flop doesn't leave the biotech a lot of options.

1 year ago - The Motley Fool

AnaptysBio Inc (NASDAQ: ANAB) shares were taking a huge hit after the company announced a clinical pipeline update along with its third-quarter report.

1 year ago - Benzinga

AnaptysBio stock crashed Friday after the biotech said its experimental eczema treatment failed to pass muster in a Phase 2 study. Shares fell to their lowest-ever point in high volume.

1 year ago - Investors Business Daily

About ANAB

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable t... [Read more...]

Industry
Biotechnology
IPO Date
Jan 26, 2017
CEO
Hamza Suria
Employees
94
Stock Exchange
NASDAQ
Ticker Symbol
ANAB
Full Company Profile

Financial Performance

In 2020, AnaptysBio's revenue was $75.00 million, an increase of 837.50% compared to the previous year's $8.00 million. Losses were -$19.93 million, -79.52% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for AnaptysBio stock is "Buy." The 12-month stock price forecast is 28.50, which is an increase of 31.22% from the latest price.

Price Target
$28.50
(31.22% upside)
Analyst Consensus: Buy